OTS - A new expert consensus publication provides practical guidance on the use of omega-3 fatty acids in parenteral nutrition
2020. February 17. 10:00
Bad Homburg, Germany, 17 February, 2020 (APA/OTS) - Fresenius Kabi,
a global leader in clinical nutrition, announces that the Journal
of Parenteral and Enteral Nutrition (JPEN) has recently published
"Lipids in Parenteral Nutrition: Translating Guidelines into
Clinical Practice".(1) The publication represents the largest set
of expert consensus statements to provide guidance on the use of
fish oil-containing lipid emulsions in clinical practice.
An international panel of leading experts in clinical
nutrition, lipid metabolism, and pharmacology developed a set of 43
consensus recommendations. The recommendations aim to help
healthcare professionals to navigate issues around prescription,
administration, safety, and monitoring of lipids - from short- to
long-term parenteral nutrition, from pediatric to adult patients,
from home to hospital care.
Fish oil-containing parenteral nutrition has been shown to have
a variety of beneficial effects on key biological functions,
including modulation of the immune and inflammatory response. A
growing body of evidence suggests that these properties improve
clinical outcomes, e.g. infection rates, sepsis rate, length of ICU
and hospital stay.(2)
Current guidelines of international clinical societies
recommend the use of fish oil-containing lipid emulsions in
parenteral nutrition.(3-5) Regarding specific nutrients, only
parenteral lipid emulsions with EPA + DHA* are recommended by the
European Society for Clinical Nutrition and Metabolism (ESPEN)
guideline on clinical nutrition in the intensive care unit.(4)
To read the summary of consensus statements along with the
review of current evidence on the clinical benefits of omega-3
fatty acids in parenteral nutrition across the healthcare
continuum, visit
https://onlinelibrary.wiley.com/toc/19412444/2020/44/S1.
Register now for the free 2-part educational series offered by
the American Society for Parenteral and Enteral Nutrition (ASPEN)
specifically on this topic: "Expert Consensus on Omega-3 Fatty
Acids in Parenteral Nutrition: Focus on Critical Care and Major
Surgery" on April 22, 2020, and "Expert Consensus on Omega-3 Fatty
Acids in Parenteral Nutrition: Continuum of Care - From Hospital
to Home Care" on July 9, 2020. Visit the ASPEN Clinical Nutrition
Webinar Series at http://www.nutritioncare.org/webinars/.
* EPA=eicosapentaenoic acid; DHA=docosahexanoic acid
References
(1.) Martindale R, Berlana D, Boullata J, et al. Lipids in
Parenteral Nutrition: Translating Guidelines into Clinical
Practice. JPEN J Parenter Enteral Nutr. 2020;44(suppl S1):S1-S84.
(2.) Pradelli L, Mayer K, Klek S et al. ?-3 Fatty-Acid
Enriched Parenteral Nutrition in Hospitalized Patients: Systematic
Review With Meta-Analysis and Trial Sequential Analysis. JPEN J
Parenter Enteral Nutr. 2020;44(1):44-57.
(3.) McClave SA, Taylor BE, Martindale RG et al. Guidelines
for the Provision and Assessment of Nutrition Support Therapy in
the Adult Critically Ill Patient: Society of Critical Care Medicine
(SCCM) and American Society for Parenteral and Enteral Nutrition
(A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2016;40(2):159-211.
(4.) Singer P, Blaser AR, Berger MM et al. ESPEN guideline
on clinical nutrition in the intensive care unit. Clin Nutr.
2019;38(1):48-79.
(5.) Lapillonne A, Fidler Mis N, Goulet O et al.
ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral
nutrition: Lipids. Clin Nutr. 2018;37(6 Pt B):2324-36.
# # #
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes
in lifesaving medicines and technologies for infusion, transfusion
and clinical nutrition. The company's products and services are
used to help care for critically and chronically ill patients.
Fresenius Kabi's product portfolio comprises a comprehensive range
of I.V. generic drugs, infusion therapies and clinical nutrition
products as well as the devices for administering these products.
In the field of biosimilars, we focus on autoimmune diseases and
oncology. In 2019, the first biosimilar product by Fresenius Kabi
was launched. Within transfusion medicine and cell therapies,
Fresenius Kabi offers products for collection and processing of
blood and cell components.
With its corporate philosophy of "caring for life", the company
is committed to putting essential medicines and technologies in the
hands of people who help patients and finding the best answers to
the challenges they face.
For more information, please visit fresenius-kabi.com.
For press inquiries, please contact:
Nina Espiritu
Edelman GmbH
Barmbeker Str 4, 22303 Hamburg, Germany
T: +49 (0)69 401254-345
nina.espiritu@edelman.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.